

REMARKS

Claims 1-51 have been canceled; claims 52-103 have been added. Claims 52-103.

Favorable consideration of the pending claims is requested.

Claims 52-103 correspond to claims 1-55 which were allowed in the parent application, except that Applicants have separated indoles (in the present claims) from benzothiophenes (claimed in an RCE filed in the parent application, concurrently with this divisional application). No new matter is added.

Conclusion

Applicants believe all claims are now in condition for allowance. Should there be any issues that have not been addressed to the Examiner's satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees are due in connection with this response, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: March 9, 2004

sdp
Stephen D. Prodnuk
Attorney For Applicants
Registration No. 43,020

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7320
Fax: (858) 678-8233